Neuron-specific enolase is unaltered whereas S100B is elevated in serum of patients with schizophrenia - Original research and meta-analysis

Psychiatry Research

Volumn 167, Issue 1-2, 2009, Pages 66-72

  Schroeter, Matthias L ^a,b,c   Abdul Khaliq, Hashim ^d,e   Krebs, Michael ^a,f   Diefenbacher, Albert ^a   Blasig, Ingolf E ^b  

^a Queen Elisabeth Hospital   (Germany)

^b LEIBNIZ INSTITUT FÜR MOLEKULARE PHARMAKOLOGIE   (Germany)

^c UNIVERSITY OF LEIPZIG   (Germany)

^d DEUTSCHES HERZZENTRUM BERLIN   (Germany)

^e SAARLAND UNIVERSITY   (Germany)

^f HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Astrocytes; Blood brain barrier; Neuron specific enolase; Neurons; S100B; Schizophrenia

Indexed keywords

BIOLOGICAL MARKER; NEUROLEPTIC AGENT; NEURON SPECIFIC ENOLASE; PROTEIN S100B;

ADULT; ARTICLE; ASTROCYTE; BLOOD SAMPLING; CLINICAL ARTICLE; FEMALE; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; MALE; META ANALYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; SCHIZOPHRENIA;

ADULT; ASTROCYTES; BLOOD-BRAIN BARRIER; FEMALE; HUMANS; MALE; MIDDLE AGED; NERVE GROWTH FACTORS; NEURONS; PATIENT ADMISSION; PATIENT DISCHARGE; PHOSPHOPYRUVATE HYDRATASE; S100 PROTEINS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 64649086370     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psychres.2008.01.002     Document Type: Article

References (36)

1. Abdul-Khaliq H., Schubert S., Stoltenburg-Didinger G., Troitzsch D., Bottcher W., Hubler M., Meissler M., Grosse-Siestrop C., Alexi-Meskishvili V., Hetzer R., and Lange P.E. Protein S-100 beta in brain and serum after deep hypothermic circulatory arrest in rabbits: relationship to perivascular astrocytic swelling. Clinical Chemistry and Laboratory Medicine 38 (2000) 1169-1172
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. (1994), American Psychiatric Press, Washington, DC
3. American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. American Journal of Psychiatry 154 Suppl 4 (1997) 1-63
4. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. (1988), Lawrence Erlbaum Associates, Hillsdale, NJ
5. In: Collegium Internationale Psychiatriae Scalarum (Ed). Internationale Skalen für Psychiatrie (1996), Beltz-Test, Göttingen
6. Egan M.F., El-Mallakh S., Suddath R.L., Lohr J.B., Bracha H.S., and Wyatt R.J. Cerebrospinal fluid and serum levels of neuron-specific enolase in patients with schizophrenia. Psychiatry Research 43 (1992) 187-195
7. Gattaz W.F., Lara D.R., Elkis H., Portela L.V., Goncalves C.A., Tort A.B., Henna J., and Souza D.O. Decreased S100-beta protein in schizophrenia: preliminary evidence. Schizophrenia Research 43 (2000) 91-95
8. In: Haug J.H., and Stieglitz R.D. (Eds). Das AMDP-System in der klinischen Anwendung und Forschung (1997), Hogrefe, Göttingen
9. Kanner A.A., Marchi N., Fazio V., Mayberg M.R., Koltz M.T., Siomin V., Stevens G.H.J., Masaryk T., Ayumar B., Vogelbaum M.A., Barnett G.H., and Janigro D. Serum S100 - a noninvasive marker of blood-brain barrier function and brain lesions. Cancer 97 (2003) 2806-2813
10. Kapural M., Krizanac-Bengez L., Barnett G., Perl J., Masaryk T., Apollo D., Rasmussen P., Mayberg M.R., and Janigro D. Serum S-100β as a possible marker of blood-brain barrier dysfunction. Brain Research 940 (2002) 102-104
11. Lara D.R., Gama C.S., Belmonte-de-Abreu P., Portela L.V.C., Goncalves C.A., Fonseca M., Hauck S., and Souza D.O. Increased serum S100B protein in schizophrenia: a study in medication-free patients. Journal of Psychiatric Research 35 (2001) 11-14
12. Ling S.H., Tang Y.L., Jiang F., Wiste A., Guo S.S., Weng Y.Z., and Yang T.S. Plasma S-100B protein in Chinese patients with schizophrenia: comparison with healthy controls and effect of antipsychotic treatment. Journal of Psychiatric Research 41 (2007) 36-42
13. Liu J., Shi Y., Tang J., Guo T., Li X., Yang Y., Chen Q., Zhao X., He G., Feng G., Gu N., Zhu S., Liu H., and He L. SNPs and haplotypes in the S100B gene reveal association with schizophrenia. Biochemical and Biophysical Research Communications 328 (2005) 335-341
14. Marchi N., Rasmussen P., Kapural M., Fazio V., Kight K., Mayberg M.R., Kanner A., Ayumar B., Albensi B., Cavaglia M., and Janigro D. Peripheral markers of brain damage and blood-brain barrier dysfunction. Restorative Neurology and Neuroscience 21 (2003) 109-121
15. Marchi N., Cavaglia M., Fazio V., Bhudia S., Hallene K., and Janigro D. Peripheral markers of blood-brain barrier damage. Clinica Chimica Acta 342 (2004) 1-12
16. McEvoy J.P., Scheifler P.L., and Frances A. The expert consensus guideline series: treatment of schizophrenia 1999. Journal of Clinical Psychiatry 60 Suppl 11 (1999) 1-80
17. Overall J.E., and Gorham D.R. The Brief Psychiatric Rating Scale. Psychological Reports 10 (1962) 799-812
18. Pinto S.S., Gottfried C., Mendez A., Goncalves D., Karl J., Goncalves C.A., Wofchuk S., and Rodnight R. Immunocontent and secretion of S100B in astrocyte cultures from different brain regions in relation to morphology. FEBS Letters 486 (2000) 203-207
19. Potapov E.V., Loebe M., Abdul-Khaliq H., Koster A., Stein J., Sodian R., Kopitz M., Hausmann H., Noon G.P., DeBakey M.E., and Hetzer R.H. Postoperative course of S-100B protein and neuron-specific enolase in patients after implantation of continuous and pulsatile flow LVADs. Journal of Heart and Lung Transplantation 20 (2001) 1310-1316
20. Reiber H. Dynamics of brain-derived proteins in cerebrospinal fluid. Clinica Chimica Acta 310 (2001) 173-186
21. Rothermundt M., Missler U., Arolt V., Peters M., Leadbeater J., Wiesmann M., Rudolf S., Wandinger K.P., and Kirchner H. Increased S100B blood levels in unmedicated and treated schizophrenic patients are correlated with negative symptomatology. Molecular Psychiatry 6 (2001) 445-449
22. Rothermundt M., Falkai P., Ponath G., Abel S., Bürkle H., Diedrich M., Hetzel G., Peters M., Siegmund A., Pedersen A., Maier W., Schramm J., Suslow T., Ohrmann P., and Arolt V. Glial cell dysfunction in schizophrenia indicated by increased S100B in the CSF. Molecular Psychiatry 9 (2004) 897-899
23. Rothermundt M., Ponath G., and Arolt V. S100B in schizophrenic psychosis. International Review of Neurobiology 59 (2004) 445-470
24. Rothermundt M., Ponath G., Glaser T., Hetzel G., and Arolt V. S100B serum levels and long-term improvement of negative symptoms in patients with schizophrenia. Neuropsychopharmacology 29 (2004) 1004-1011
25. Rothermundt M., Ohrmann P., Abel S., Siegmund A., Pedersen A., Ponath G., Suslow T., Peters M., Kaestner F., Heindel W., Arolt V., and Pfleiderer B. Glial cell activation in a subgroup of patients with schizophrenia indicated by increased S100B serum concentrations and elevated myo-inositol. Progress in Neuro-Psychopharmacology & Biological Psychiatry 31 (2007) 361-364
26. Schäfer B., and Heizmann C. The S100 family of EF-hand calcium-binding proteins: function and pathology. Trends in Biochemical Sciences 21 (1996) 134-140
27. Schmitt A., Bertsch T., Henning U., Tost H., Klimke A., Henn F.A., and Falkai P. Increased serum S100B in elderly, chronic schizophrenic patients: negative correlation with deficit symptoms. Schizophrenia Research 80 (2005) 305-313
28. Schroeter M.L., Mertsch K., Giese H., Müller S., Sporbert A., Hickel B., and Blasig I.E. Astrocytes enhance radical defence in capillary endothelial cells constituting the blood-brain barrier. FEBS Letters 449 (1999) 241-244
29. Schroeter M.L., Müller S., Lindenau J., Wiesner B., Hanisch U.K., Wolf G., and Blasig I.E. Astrocytes induce manganese superoxide dismutase in brain capillary endothelial cells. Neuroreport 12 (2001) 2513-2517
30. Schroeter M.L., Abdul-Khaliq H., Diefenbacher A., and Blasig I.E. S100B is increased in mood disorders and may be reduced by antidepressive treatment. Neuroreport 13 (2002) 1675-1678
31. Schroeter M.L., Abdul-Khaliq H., Diefenbacher A., and Blasig I.E. Serum S100B is increased during early treatment with antipsychotics and in deficit schizophrenia. Schizophrenia Research 62 (2003) 231-236
32. Steiner J., Bielau H., Bernstein H.G., Bogerts B., and Wunderlich M.T. Increased cerebrospinal fluid and serum levels of S100B in first-onset schizophrenia are not related to a degenerative release of glial fibrillar acidic protein, myelin basic protein and neurone-specific enolase from glia or neurones. Journal of Neurology, Neurosurgery and Psychiatry 77 (2006) 1284-1287
33. Wiesmann M., Wandinger K.P., Missler U., Eckhoff D., Rothermund M., Arolt V., and Kirchner H. Elevated plasma levels of S-100b protein in schizophrenic patients. Biological Psychiatry 45 (1999) 1508-1511
34. World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Diagnostic Criteria for Research (DCR) (1993), WHO, Geneva
35. Zachrisson O.C.G., Balldin J., Ekman R., Naesh O., Rosengren L., Agren H., and Blennow K. No evident neuronal damage after electroconvulsive therapy. Psychiatry Research 96 (2000) 157-165
36. Zimmer D.B., Cornwall E.H., Landar A., and Song W. The S100 protein family: history, function, and expression. Brain Research Bulletin 37 (1995) 417-429